Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Citrus + Cydonia comp. (marketed under the brand name **Gencydo**) is an anthroposophic medicinal product developed by **Weleda AG** for the treatment of seasonal allergic rhinitis (hay fever). It is a botanical preparation consisting of extracts from lemon juice (*Citrus limon*) and an aqueous extract of quince fruit (*Cydonia oblonga*). The drug acts as an immunomodulator by selectively influencing T-cell differentiation; specifically, it promotes the production of interleukin-10 (IL-10) over interleukin-12 (IL-12) and induces regulatory T-cell subsets. This mechanism helps to restore the Th1/Th2 immunological balance that is typically disrupted in allergic conditions. It has been evaluated in Phase 3 clinical trials as a 1% solution for subcutaneous injection and is also available in other forms such as a nasal spray.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Citrus + Cydonia comp..